The incidence rate of the primary end point increased in a stepwise manner with increases in urinary L-FABP.
From randomization to end of study OHSA item 1 (dizziness/lightheadedness, the primary efficacy end point) increased (ie, symptom worsened) by 1.3±2.8 units in the droxidopa group versus 1.9±3.2 in the placebo group (P=0.509).
Highlighting the total effect of the 0.05 mg/kg/day teduglutide dose, the composite end point increased significantly by 816±982 ml/day compared with placebo (p=0.03) at week 20.
The unadjusted incidence of the composite primary end point increased with increasing hsTnI category, from 0.56 per 100 person-years in the first tertile to 1.74 events per 100 person-years in the third tertile (P<0.0001; Table 2 and Figure 1A).
The unadjusted incidence of the composite primary end point increased with increasing BNP category, from 0.65 per 100 person-years in the first tertile to 1.73 events per 100 person-years in the third tertile (P<0.0001; Table 2 and Figure 1B).
The basis of the induction approach is to estimate an action spectrum that is described by fewer parameters than the number of sources used, calculate the weighted dose for an appropriate end point (increased NFAT transcriptional activity of 3-fold) and compare these calculated doses with those actually observed.
The 6 min walk distance (primary end point) increased in all ambrisentan arms; mean placebo-corrected treatment effects were 31 m (P = 0.008) and 51 m (P < 0.001) in ARIES-1, respectively, and 32 m (P = 0.022) and 59 m (P < 0.001) in ARIES-2, respectively.
All DR prevalence end points increased with diabetes duration, hemoglobin A1c, and blood pressure levels and were higher in people with type 1 compared with type 2 diabetes.
In this context, animals must be killed at pre-determined end points, increasing the number of animals required and limiting the possibility of ongoing observation of tumour progression within the same animal.
According to the new meta analysis data in 2013, All DR prevalence end points increased with diabetes duration, hemoglobin A1c, and blood pressure levels and were higher in people with type 1 compared with type 2 diabetes [ 5].
